Cell therapy for liver disease: From liver transplantation to cell factory

Stuart J. Forbes, Sanjeev Gupta, Anil Dhawan

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

Work over several decades has laid solid foundations for the advancement of liver cell therapy. To date liver cell therapy in people has taken the form of hepatocyte transplantation for metabolic disorders with a hepatic basis, and for acute or chronic liver failure. Although clinical trials using various types of autologous cells have been implemented to promote liver regeneration or reduce liver fibrosis, clear evidence of therapeutic benefits have so far been lacking. Cell types that have shown efficacy in preclinical models include hepatocytes, liver sinusoidal endothelial cells, mesenchymal stem cells, endothelial progenitor cells, and macrophages. However, positive results in animal models have not always translated through to successful clinical therapies and more realistic preclinical models need to be developed. Studies defining the optimal repopulation by transplanted cells, including routes of cell transplantation, superior engraftment and proliferation of transplanted cells, as well as optimal immunosuppression regimens are required. Tissue engineering approaches to transplant cells in extrahepatic locations have also been proposed. The derivation of hepatocytes from pluripotent or reprogramed cells raises hope that donor organ and cell shortages could be overcome in the future. Critical hurdles to be overcome include the production of hepatocytes from pluripotent cells with equal functional capacity to primary hepatocytes and long-term phenotypic stability in vivo.

Original languageEnglish (US)
Pages (from-to)S157-S169
JournalJournal of Hepatology
Volume62
Issue numberS1
DOIs
StatePublished - 2015

Fingerprint

Cell- and Tissue-Based Therapy
Liver Transplantation
Liver Diseases
Hepatocytes
Liver
End Stage Liver Disease
Liver Regeneration
Acute Liver Failure
Cell Transplantation
Tissue Engineering
Mesenchymal Stromal Cells
Liver Cirrhosis
Immunosuppression
Endothelial Cells
Animal Models
Transplantation
Macrophages
Cell Proliferation
Tissue Donors
Clinical Trials

Keywords

  • Cell therapy
  • Liver cirrhosis
  • Liver regeneration
  • Metabolic liver disease
  • Stem cells

ASJC Scopus subject areas

  • Hepatology

Cite this

Cell therapy for liver disease : From liver transplantation to cell factory. / Forbes, Stuart J.; Gupta, Sanjeev; Dhawan, Anil.

In: Journal of Hepatology, Vol. 62, No. S1, 2015, p. S157-S169.

Research output: Contribution to journalArticle

Forbes, Stuart J. ; Gupta, Sanjeev ; Dhawan, Anil. / Cell therapy for liver disease : From liver transplantation to cell factory. In: Journal of Hepatology. 2015 ; Vol. 62, No. S1. pp. S157-S169.
@article{f4967571420044d39fb8e4ff371ac64c,
title = "Cell therapy for liver disease: From liver transplantation to cell factory",
abstract = "Work over several decades has laid solid foundations for the advancement of liver cell therapy. To date liver cell therapy in people has taken the form of hepatocyte transplantation for metabolic disorders with a hepatic basis, and for acute or chronic liver failure. Although clinical trials using various types of autologous cells have been implemented to promote liver regeneration or reduce liver fibrosis, clear evidence of therapeutic benefits have so far been lacking. Cell types that have shown efficacy in preclinical models include hepatocytes, liver sinusoidal endothelial cells, mesenchymal stem cells, endothelial progenitor cells, and macrophages. However, positive results in animal models have not always translated through to successful clinical therapies and more realistic preclinical models need to be developed. Studies defining the optimal repopulation by transplanted cells, including routes of cell transplantation, superior engraftment and proliferation of transplanted cells, as well as optimal immunosuppression regimens are required. Tissue engineering approaches to transplant cells in extrahepatic locations have also been proposed. The derivation of hepatocytes from pluripotent or reprogramed cells raises hope that donor organ and cell shortages could be overcome in the future. Critical hurdles to be overcome include the production of hepatocytes from pluripotent cells with equal functional capacity to primary hepatocytes and long-term phenotypic stability in vivo.",
keywords = "Cell therapy, Liver cirrhosis, Liver regeneration, Metabolic liver disease, Stem cells",
author = "Forbes, {Stuart J.} and Sanjeev Gupta and Anil Dhawan",
year = "2015",
doi = "10.1016/j.jhep.2015.02.040",
language = "English (US)",
volume = "62",
pages = "S157--S169",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "S1",

}

TY - JOUR

T1 - Cell therapy for liver disease

T2 - From liver transplantation to cell factory

AU - Forbes, Stuart J.

AU - Gupta, Sanjeev

AU - Dhawan, Anil

PY - 2015

Y1 - 2015

N2 - Work over several decades has laid solid foundations for the advancement of liver cell therapy. To date liver cell therapy in people has taken the form of hepatocyte transplantation for metabolic disorders with a hepatic basis, and for acute or chronic liver failure. Although clinical trials using various types of autologous cells have been implemented to promote liver regeneration or reduce liver fibrosis, clear evidence of therapeutic benefits have so far been lacking. Cell types that have shown efficacy in preclinical models include hepatocytes, liver sinusoidal endothelial cells, mesenchymal stem cells, endothelial progenitor cells, and macrophages. However, positive results in animal models have not always translated through to successful clinical therapies and more realistic preclinical models need to be developed. Studies defining the optimal repopulation by transplanted cells, including routes of cell transplantation, superior engraftment and proliferation of transplanted cells, as well as optimal immunosuppression regimens are required. Tissue engineering approaches to transplant cells in extrahepatic locations have also been proposed. The derivation of hepatocytes from pluripotent or reprogramed cells raises hope that donor organ and cell shortages could be overcome in the future. Critical hurdles to be overcome include the production of hepatocytes from pluripotent cells with equal functional capacity to primary hepatocytes and long-term phenotypic stability in vivo.

AB - Work over several decades has laid solid foundations for the advancement of liver cell therapy. To date liver cell therapy in people has taken the form of hepatocyte transplantation for metabolic disorders with a hepatic basis, and for acute or chronic liver failure. Although clinical trials using various types of autologous cells have been implemented to promote liver regeneration or reduce liver fibrosis, clear evidence of therapeutic benefits have so far been lacking. Cell types that have shown efficacy in preclinical models include hepatocytes, liver sinusoidal endothelial cells, mesenchymal stem cells, endothelial progenitor cells, and macrophages. However, positive results in animal models have not always translated through to successful clinical therapies and more realistic preclinical models need to be developed. Studies defining the optimal repopulation by transplanted cells, including routes of cell transplantation, superior engraftment and proliferation of transplanted cells, as well as optimal immunosuppression regimens are required. Tissue engineering approaches to transplant cells in extrahepatic locations have also been proposed. The derivation of hepatocytes from pluripotent or reprogramed cells raises hope that donor organ and cell shortages could be overcome in the future. Critical hurdles to be overcome include the production of hepatocytes from pluripotent cells with equal functional capacity to primary hepatocytes and long-term phenotypic stability in vivo.

KW - Cell therapy

KW - Liver cirrhosis

KW - Liver regeneration

KW - Metabolic liver disease

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=84938079812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938079812&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2015.02.040

DO - 10.1016/j.jhep.2015.02.040

M3 - Article

C2 - 25920085

AN - SCOPUS:84938079812

VL - 62

SP - S157-S169

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - S1

ER -